Ranitidine prophylaxis in acute gastric mucosal damage in critically ill pediatric patients

Area of Science:

• Pediatric critical care medicine
• Pharmacology
• Gastroenterology

Background:

• Critically ill children are at high risk for acute gastric mucosal damage (AGMD).
• Effective gastric acid inhibition is crucial for AGMD prophylaxis in pediatric intensive care units.

Purpose of the Study:

• To determine the optimal ranitidine dosage for maintaining gastric pH ≥ 4 in critically ill children.
• To evaluate the efficacy of different ranitidine administration routes and frequencies for gastric acid control.

Main Methods:

• Forty critically ill children were divided into four groups.
• Ranitidine was administered via nasogastric (NG) tube (2 and 4 mg/kg every 12h) or intravenously (IV) (0.75 and 1.5 mg/kg every 6h).
• Gastric pH was monitored to assess the effectiveness of ranitidine in maintaining a pH at or above 4.

Main Results:

• The group receiving 1.5 mg/kg IV every 6 hours achieved a higher median gastric pH compared to other groups.
• 80% of patients in the 1.5 mg/kg IV every 6h group maintained a pH ≥ 4 for over 80% of the study period.
• This group also had the highest risk profile for acute gastric mucosal damage.

Conclusions:

• A dosage of 1.5 mg/kg of ranitidine administered intravenously every 6 hours is recommended for effective gastric acid inhibition.
• This regimen is suggested for the prophylaxis of acute gastric mucosal damage in critically ill children.
• Intravenous ranitidine at 1.5 mg/kg every 6 hours provides superior gastric acid control in this pediatric population.